Vivmark Residential Common Shares of Beneficial Interest (NYSE:VMRK – Get Free Report) Director Chris Carr sold 1,130 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $65.28, for a total transaction of $73,766.40. Following the transaction, the director owned 4,461 shares of the company’s stock, valued at approximately $291,214.08. The trade was a 20.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Vivmark Residential Common Shares of Beneficial Interest Stock Performance
NYSE VMRK traded up $0.50 during midday trading on Friday, hitting $65.52. The company had a trading volume of 6,724,558 shares, compared to its average volume of 3,264,781. Vivmark Residential Common Shares of Beneficial Interest has a fifty-two week low of $57.57 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.19 and a quick ratio of 0.19. The firm has a market capitalization of $24.57 billion, a price-to-earnings ratio of 28.49, a P/E/G ratio of 3.56 and a beta of 0.73.
Vivmark Residential Common Shares of Beneficial Interest (NYSE:VMRK – Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $0.30 EPS for the quarter. Vivmark Residential Common Shares of Beneficial Interest had a net margin of 27.97% and a return on equity of 8.06%. The business had revenue of $785.05 million during the quarter. Equities research analysts forecast that Vivmark Residential Common Shares of Beneficial Interest will post 4.07 EPS for the current year.
Institutional Trading of Vivmark Residential Common Shares of Beneficial Interest
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on VMRK. Mizuho raised Vivmark Residential Common Shares of Beneficial Interest from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $70.00 to $73.00 in a report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 target price on shares of Vivmark Residential Common Shares of Beneficial Interest in a research note on Tuesday, August 25th. Wells Fargo & Company assumed coverage on Vivmark Residential Common Shares of Beneficial Interest in a research report on Friday, August 21st. They issued an “overweight” rating and a $72.00 target price for the company. KeyCorp initiated coverage on shares of Vivmark Residential Common Shares of Beneficial Interest in a research note on Wednesday, August 26th. They set a “sector weight” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Vivmark Residential Common Shares of Beneficial Interest in a report on Monday, August 24th. They issued a “neutral” rating and a $73.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Vivmark Residential Common Shares of Beneficial Interest currently has an average rating of “Hold” and an average price target of $73.85.
Check Out Our Latest Research Report on VMRK
Vivmark Residential Common Shares of Beneficial Interest Company Profile
Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, DC, Seattle, San Francisco, Southern California and Denver.
See Also
- Five stocks we like better than Vivmark Residential Common Shares of Beneficial Interest
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Vivmark Residential Common Shares of Beneficial Interest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivmark Residential Common Shares of Beneficial Interest and related companies with MarketBeat.com's FREE daily email newsletter.
